Alnylam Pharmaceuticals Inc (ALNY)

242.50 -0.75 (-0.31%) USD  |  NASDAQ  |  Dec 26, 16:00
239.61 -2.89 (-1.19%) Pre-Market: 08:10
More

Alnylam Pharmaceuticals Research and Development Expense (Quarterly): 270.93M for Sept. 30, 2024

Research and Development Expense (Quarterly) Chart

View Research and Development Expense (Quarterly) for ALNY.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Quarterly) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

View Research and Development Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Quarterly) Benchmarks

View Research and Development Expense (Quarterly) Benchmarks
Start Trial
Pfizer Inc 2.598B
BridgeBio Pharma Inc 120.44M
Gilead Sciences Inc 1.395B
Regeneron Pharmaceuticals Inc 1.272B
Sarepta Therapeutics Inc 224.48M